Menu
Back to Journals » ImmunoTargets and Therapy » Volume 12
ImmunoTargets and Therapy
ISSN: 2253-1556
- View all (171)
- Volume 13, 2024 (16)
- Volume 12, 2023 (14)
- Volume 11, 2022 (6)
- Volume 10, 2021 (30)
- Volume 9, 2020 (27)
- Volume 8, 2019 (5)
- Volume 7, 2018 (10)
- Volume 6, 2017 (8)
- Volume 5, 2016 (8)
- Volume 4, 2015 (17)
- Volume 3, 2014 (14)
- Volume 2, 2013 (13)
- Volume 1, 2012 (3)
Archive: Volume 12, 2023
Extended-Release Tofacitinib Therapy for a MDA5 Antibody-Positive Amyopathic Dermatomyositis Patient with Early-Stage Interstitial Lung Disease
Wang CR, Lin WC, Wong TW
ImmunoTargets and Therapy 2023, 12:187-192
Published Date: 20 December 2023
Managing Cardiovascular Risk in Systemic Lupus Erythematosus: Considerations for the Clinician
Semalulu T, Tago A, Zhao K, Tselios K
ImmunoTargets and Therapy 2023, 12:175-186
Published Date: 8 December 2023
NOTCH1 Mutations Predict Superior Outcomes of Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
Huang Q, Cao H, Yao Q, Zhou X, Li H, Bai Q, Hu H
ImmunoTargets and Therapy 2023, 12:165-173
Published Date: 5 December 2023
The Methylation in B7-H4 and BTLA Genes are Associated with the Risk of Pulmonary Tuberculosis
Cai XQ, Huang Q, Zhang TP
ImmunoTargets and Therapy 2023, 12:149-163
Published Date: 24 November 2023
Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication Genes
Jiang J, Wang Y, Liu D, Wang X, Zhu Y, Tong J, Chen E, Xue L, Zhao N, Liang T, Zheng C
ImmunoTargets and Therapy 2023, 12:135-147
Published Date: 23 November 2023
Comparative Efficacy and Safety of Neoadjuvant Immunotherapy with Chemotherapy versus Chemotherapy Alone in Non-Small Cell Lung Cancer: A Propensity Score and Inverse Probability Treatment Weighting Analysis
Zhao J, Hao S, Li Y, Liu X, Liu Z, Zheng C, Han D
ImmunoTargets and Therapy 2023, 12:113-133
Published Date: 11 November 2023
Globoid Cell Leukodystrophy (Krabbe Disease): An Update
Maghazachi AA
ImmunoTargets and Therapy 2023, 12:105-111
Published Date: 31 October 2023
Exploration of Immune Targets for Type 1 Diabetes and Latent Autoimmune Disease Immunotherapy
Siddiqui K, Nawaz SS
ImmunoTargets and Therapy 2023, 12:91-103
Published Date: 29 September 2023
Towards Early Diagnosis of Mixed Connective Tissue Disease: Updated Perspectives
Ferrara CA, La Rocca G, Ielo G, Libra A, Sambataro G
ImmunoTargets and Therapy 2023, 12:79-89
Published Date: 26 July 2023
Dupilumab Treatment is Not Associated with Increased Risk of Overall Skin Infections [Letter]
Wiggins S, Levit NA
ImmunoTargets and Therapy 2023, 12:77-78
Published Date: 25 May 2023
Association of Toll-like Receptors 1, 2, 4, 6, 8, 9 and 10 Genes Polymorphisms and Susceptibility to Pulmonary Tuberculosis in Sudanese Patients
Mhmoud NA
ImmunoTargets and Therapy 2023, 12:47-75
Published Date: 6 April 2023
Novel Immunotherapies for Myasthenia Gravis
Nair SS, Jacob S
ImmunoTargets and Therapy 2023, 12:25-45
Published Date: 4 April 2023
A Case of Complete Remission in Proficient Mismatch Repair (pMMR) Advanced Colon Cancer Treated with Sintilimab and XELOX
Zhu J, Li G, Zhang Z, Wang Y
ImmunoTargets and Therapy 2023, 12:17-23
Published Date: 19 February 2023
Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Wang X, Guo Z, Wu X, Chen D, Wang F, Yang L, Luo M, Wu S, Yang C, Huang L, Fu L
ImmunoTargets and Therapy 2023, 12:1-16
Published Date: 4 January 2023